Trial Profile
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms HOPE
- 03 Aug 2022 Primary endpoint (Overall Survival) has not been met, according to the results published in the European Journal of Cancer.
- 03 Aug 2022 Results assessing the the efficacy and safety of lenvatinib for anaplastic thyroid cancer published in the European Journal of Cancer
- 16 Jun 2020 Status changed from active, no longer recruiting to completed.